For four decades, American obesity only moved one direction — from 15% in the late 1970s past 40% by 2023.
That just changed.
The adult obesity rate dropped from 39.9% in 2022 to 37.0% — roughly 7.6 million fewer obese adults in three years. Adults reporting GLP-1 use jumped to 12.4% from 5.8% in February 2024. Decades of food pyramids never moved this line. One drug class did it in thirty-six months.
The Manufacturers
The dominant US-based GLP-1 maker is firing on all cylinders. Q1 2026 revenue hit $19.8B, up 56% YoY, with full-year guidance raised by $2B. Our Main Street score sits at 52, with a LikeFolio Score of 77 — real demand, but a meaningful portion already reflected in the tape.
The Danish incumbent that pioneered the category tells a different story. Consumer demand remains healthy (Main Street 52), but institutional conviction has cooled to 48 on Wall Street as share shifts to its US rival. LikeFolio Score 58. A franchise that built the market but is fighting to keep it.
The Distribution Play
A fast-growing direct-to-consumer telehealth platform settled its dispute with the Danish manufacturer on March 9, 2026, signed a direct supply agreement, and is winding down compounded semaglutide by mid-2026. It now distributes both branded GLP-1 franchises — effectively becoming the consumer-facing front door to the entire category.
Its Weight Loss vertical hit $100M annual revenue in roughly nine months, with users self-reporting 22–29 pounds of first-year weight loss. The platform carries a Main Street Score of 69 — the highest in the entire GLP-1 complex — and a LikeFolio Score of 75.
The stock recently took a sharp drawdown. The market sees a margin headwind from the new supply structure. We see something very different: the moment this company stopped being a regulatory risk story and became a distribution franchise sitting on top of the most powerful drug class of the decade.
The Optionality
A clinical-stage biotech is advancing an oral and injectable obesity candidate, with two Phase 3 studies nearly fully enrolled. Published data shows 14.7% weight loss after 13 weeks with no plateau. Main Street 46, LikeFolio Score 48. This is binary biotech in its purest form: pivotal data either makes it a takeout target for one of the two GLP-1 majors, or the equity gets cut in half overnight.
The Roadkill
The legacy weight-loss brand that defined the pre-GLP-1 era filed Chapter 11 on May 6, 2025. Q1 2026 revenue fell to $168.3M with a $52.0M net loss and $465.0M in high-rate term debt. Main Street 46, LikeFolio Score 44. The Wall Street Score of 64 is the real disconnect — sell-side analysts still model a turnaround. Consumer data flatly disagrees.
What Matters
One name in this complex is being mispriced — graded by the market on a single quarter of restructuring noise, while the underlying consumer data points to a decade of distribution power across the most-prescribed therapeutic class in modern memory.
That's the name sitting in our Core Conviction playbook right now, with a specific entry, a specific target, and a thesis built on years of consumer signal — not one earnings print.
Pro subscribers get the ticker, the entry price, the price target, and the full position thesis. If you want the actual call behind this teardown — including which of the five names we're playing and how — that's behind the Pro paywall.